Observational studyEuropean urology2026
Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT Study.
Abstract readMulticenter StudyObservational Study
In one paragraph
Observational study in European urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- The 'Prostate Cancer Screening for People at Genetic Risk of Aggressive Disease' (PATROL) study.BJU international · 2026Observational
- Prostate Cancer Screening in Contemporary Era: PSA-Based Testing and Risk-Adapted Approaches.Cancers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
120 authors.
Elizabeth K BancroftOncogenetics Team, Genetics and Epidemiology, The Institute of Cancer Research, London, UK; Cancer Genetics Unit and Academic Urology Unit, The Royal Marsden NHS Foundation Trust, London, UK.
Elizabeth C PageOncogenetics Team, Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Jana McHughOncogenetics Team, Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Sarah ThomasCancer Genetics Unit and Academic Urology Unit, The Royal Marsden NHS Foundation Trust, London, UK.
Natalie TaylorCancer Genetics Unit and Academic Urology Unit, The Royal Marsden NHS Foundation Trust, London, UK.
Jennifer PopeOncogenetics Team, Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
D Gareth EvansDepartment of Genomic Medicine, Division of Evolution, Infection and Genomic Sciences, University of Manchester, Manchester, UK.
Jeanette RothwellGenetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
Eli Marie GrindedalDepartment of Medical Genetics, Oslo University Hospital, Oslo, Norway.
Lovise MaehleDepartment of Medical Genetics, Oslo University Hospital, Oslo, Norway.
Paul JamesParkville Familial Cancer Centre, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Department of Genetic Medicine, Royal Melbourne Hospital, Parkville, Australia.
Joanne McKinleyParkville Familial Cancer Centre, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.
Lyon MascarenhasParkville Familial Cancer Centre, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.
Lucy SideWessex Clinical Genetics Service, Princess Anne Hospital, Southampton, UK.
Tessy ThomasWessex Clinical Genetics Service, Princess Anne Hospital, Southampton, UK.
Monique E van LeerdamDutch Foundation for Detection of Hereditary Tumors, Leiden, The Netherlands; Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands.
Christi J van AsperenDepartment of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands.
Lambertus A L M KiemeneyRadboud University Medical Center, Nijmegen, The Netherlands.
Janneke RingelbergDutch Foundation for Detection of Hereditary Tumors, Leiden, The Netherlands.
Michiel VlamingDepartment of Genetics, Division Laboratories, Pharmacy and Biomedical Genetics, University Medical Centre Utrecht, Utrecht, The Netherlands.
Karina RønlundDepartment of Clinical Genetics, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark.
Palle J S OstherDepartment of Urology, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark.
Brian T HelfandJohn and Carol Walter Center for Urological Health, Division of Urology, Endeavor Health NorthShore University HealthSystem, Evanston, IL, USA.
Christina G HuttenInternal Medicine Epidemiology, Rush Institute for Healthy Aging, Rush University Medical Center, Chicago, IL, USA.
Rogier A OldenburgDepartment of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands.
Cezary CybulskiDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University in Szczecin, Szczecin, Poland.
Dominika WokolorczykDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University in Szczecin, Szczecin, Poland.
Kai-Ren OngDepartment of Clinical Genetics, Birmingham Women's Hospital, Birmingham, UK.
Camilla HuberDepartment of Clinical Genetics, Birmingham Women's Hospital, Birmingham, UK.
Monica SalinasHereditary Cancer Program, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute, Barcelona, Spain.
Lidia FeliubadalóHereditary Cancer Program, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute, Barcelona, Spain.
Jan C OosterwijkUniversity of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Wendy A G van Zelst-StamsDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands; Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands.
Jackie CookSheffield Clinical Genetics Service, Sheffield Children's NHS Foundation Trust, Sheffield, UK.
Derek J RosarioRoyal Hallamshire Hospital, Sheffield, UK.
Kara MaxwellBasser Research Center, University of Pennsylvania, Philadelphia, PA, USA.
Jacquelyn PowersBasser Research Center, University of Pennsylvania, Philadelphia, PA, USA.
Saundra BuysHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Jo LymanHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Margreet G E M AusemsDepartment of Genetics, Division Laboratories, Pharmacy and Biomedical Genetics, University Medical Centre Utrecht, Utrecht, The Netherlands.
Rita K SchmutzlerCenter for Familial Breast and Ovarian Cancer and Center for Integrated Oncology (CIO), Faculty of Medicine, University Hospital Cologne, Cologne, Germany.
Kerstin RhiemCenter for Familial Breast and Ovarian Cancer and Center for Integrated Oncology (CIO), Faculty of Medicine, University Hospital Cologne, Cologne, Germany.
Louise IzattClinical Genetics Service, Guy's and St. Thomas' NHS Foundation Trust, London, UK.
Vishakha TripathiClinical Genetics Service, Guy's and St. Thomas' NHS Foundation Trust, London, UK.
Manuel R TeixeiraDepartment of Laboratory Genetics and IPO Porto Research Center, Portuguese Oncology Institute (IPO Porto), Porto, Portugal; School of Medicine and Biomedical Sciences (ICBAS), University of Porto, Porto, Portugal.
Marta CardosoDepartment of Laboratory Genetics and IPO Porto Research Center, Portuguese Oncology Institute (IPO Porto), Porto, Portugal.
William D FoulkesCancer Research Program, Research Institute of McGill University Health Centre, Montreal, Canada; Lady Davis Institute and Division of Medical Genetics, Jewish General Hospital, McGill University, Montreal, Canada.
Armen AprikianCancer Research Program, Research Institute of McGill University Health Centre, Montreal, Canada; Departments of Surgery and Oncology, McGill University, Montreal, Canada.
Rosemarie DavidsonWest of Scotland Genetic Service, Queen Elizabeth University Hospital, Glasgow, UK.
Mark LongmuirWest of Scotland Genetic Service, Queen Elizabeth University Hospital, Glasgow, UK.
Mariëlle W G RuijsDepartment of Clinical Genetics, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Eveline W BlomDepartment of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands.
Klaartje van EngelenDepartment of Human Genetics, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Rachel WilliamsSchool of Clinical Medicine, UNSW Medicine & Health, University of New South Wales, Sydney, Australia; Hereditary Cancer Centre, Prince of Wales Hospital, Randwick, Australia.
Lesley AndrewsPrince of Wales Clinical School, Faculty of Medicine, University of New South Wales, Sydney, Australia; Hereditary Cancer Centre, Prince of Wales Hospital, Randwick, Australia.
Declan G MurphyThe Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.
Sibel SayaDepartment of General Practice and Primary Care, University of Melbourne, Melbourne, Australia.
Dorothy HallidayOxford Centre for Genomic Medicine, Oxford University Hospitals NHS Trust, Oxford, UK.
Lisa WalkerOxford Centre for Genomic Medicine, Oxford University Hospitals NHS Trust, Oxford, UK.
Annelie LiljegrenKarolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.
Stefan CarlssonKarolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.
Ashraf AzzabiNorthern Genetics Service, Newcastle upon Tyne Hospitals, Newcastle upon Tyne, UK.
Irene JobsonNorthern Genetics Service, Newcastle upon Tyne Hospitals, Newcastle upon Tyne, UK.
Katie SnapeSt. George's Hospital, London, UK.
Merrie GowieSt. George's Hospital, London, UK.
Marion HarrisFamilial Cancer Centre, Monash Health, Clayton, Australia.
Marc TischkowitzEast Anglian Medical Genetics Service, Cambridge University Hospitals NHS Trust, Cambridge, UK; Department of Genomic Medicine, NIHR Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK.
Amy TaylorEast Anglian Medical Genetics Service, Cambridge University Hospitals NHS Trust, Cambridge, UK.
Judy KirkFamilial Cancer Service, Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, Australia; Centre for Cancer Research, Westmead Institute for Medical Research, Sydney Medical School, University of Sydney, Sydney, Australia.
Rachel SusmanGenetic Health Queensland, Royal Brisbane & Women's Hospital, Herston, Australia.
Rakefet Chen-ShtoyermanThe Adelson School of Medicine and Department of Molecular Biology, Ariel University, Ariel, Israel; The Genetic Institute, Kaplan Medical Center, Rehovot, Israel.
Allan SpigelmanHunter Family Cancer Service, Waratah, Australia; St. Vincent's Clinical School, University of New South Wales, Sydney, Australia; Cancer Genetics Clinic, The Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, Australia.
Nicholas PachterGenetic Services of Western Australia, King Edward Memorial Hospital, Subiaco, Australia; Faculty of Health and Medical Sciences, University of Western Australia, Perth, Australia.
Munaza AhmedNorth East Thames Regional Genetics Service, Great Ormond Street Hospital NHS Foundation Trust, London, UK.
Teresa Ramon Y CajalHospital de Sant Pau, Barcelona, Spain.
Mateja KrajcInstitute of Oncology, Ljubljana, Slovenia.
Ruth CleaverDepartment of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, UK.
Mara CruellasHereditary Cancer Genetics Group, Medical Oncology Department, Hospital Vall d'Hebron, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Medical Oncology Department, Hospital Clínico Univesitario Lozano Blesa, Zaragoza, Spain.
Eduard Perez-BallesteroHereditary Cancer Genetics Group, Medical Oncology Department, Hospital Vall d'Hebron, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Angela F BradyNorth West Thames Regional Genetics Service, Northwick Park Hospital, London North West University Healthcare NHS Trust, Harrow, UK.
David GallagherSt. James's Hospital, Dublin, Ireland.
Alan DonaldsonSt. Michael's Hospital, Bristol, UK.
Julian BarwellUniversity of Leicester, Leicester, UK; University Hospitals Leicester, Leicester, UK.
Nicola NicolaiFondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Eitan FriedmanChaim Sheba Medical Center, Tel-Hashomer, Israel.
Michael J HallFox Chase Cancer Center, Philadelphia, PA, USA.
Lynn GreenhalghClinical Genetics Service, Liverpool Women's Hospital, Liverpool, UK.
Vedang MurthyRadiation Oncology, Advanced Centre for Treatment Research and Education in Cancer (ACTREC), Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
Lucia CopakovaNational Cancer Institute, Bratislava, Slovakia.
John S McGrathNorth Bristol NHS Trust, Bristol, UK; University of Exeter Medical School, Exeter, UK.
Peter CookeNew Cross Hospital, Wolverhampton, UK.
Banu ArunMD Anderson Cancer Center, University of Texas, Houston, TX, USA.
Kathryn MyhillCancer Genetics Unit and Academic Urology Unit, The Royal Marsden NHS Foundation Trust, London, UK.
Matthew HogbenCancer Genetics Unit and Academic Urology Unit, The Royal Marsden NHS Foundation Trust, London, UK.
Syed HussainOncogenetics Team, Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Neil K AaronsonDivision of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Audrey Ardern-JonesCancer Genetics Unit and Academic Urology Unit, The Royal Marsden NHS Foundation Trust, London, UK.
Chris H BangmaDepartment of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Elena CastroHospital Universitario 12 de Octubre, Madrid, Spain.
David DearnaleyDivision of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK.
Diana M EcclesWessex Clinical Genetics Service, Princess Anne Hospital, Southampton, UK; Cancer Sciences, The University of Southampton, Southampton, UK.
Karen TrickerGenetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
Alison FalconerImperial College Healthcare NHS Trust, London, UK.
Henrik GronbergDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Freddie C HamdyChurchill Hospital, Oxford, UK; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Vincent KhooCancer Genetics Unit and Academic Urology Unit, The Royal Marsden NHS Foundation Trust, London, UK; St. George's Hospital, London, UK; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK; Department of Medicine, The University of Melbourne, Parkville, Australia.
Hans LiljaDepartment of Translational Medicine, Lund University, Malmö, Sweden; Departments of Pathology and Laboratory Medicine, Surgery and Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Geoffrey J LindemanParkville Familial Cancer Centre, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia; Department of Medicine, The University of Melbourne, Parkville, Australia; Cancer Biology and Stem Cells Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.
Jan LubinskiDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University in Szczecin, Szczecin, Poland.
Karol AxcronaDepartment of Urology, Akershus University Hospital, Lørenskog, Norway.
Christos MikropoulosRoyal Surrey Hospital, Guildford, UK.
Anita MitraUniversity College London Hospitals NHS Foundation Trust, London, UK.
Judith OffmanCentre for Cancer Screening, Prevention and Early Diagnosis, Wolfson Institute of Population Health, Queen Mary University, London, UK.
Gad RennertTechnion-Israel Institute of Technology, Haifa, Israel.
Mohnish SuriNottingham City Hospital, Nottingham, UK.
Tim DudderidgeUniversity Hospital Southampton, Southampton, UK.
IMPACT Study Collaborators
Mark N BrookOncogenetics Team, Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Zsofia Kote-JaraiOncogenetics Team, Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Rosalind A EelesOncogenetics Team, Genetics and Epidemiology, The Institute of Cancer Research, London, UK; Cancer Genetics Unit and Academic Urology Unit, The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: ros.eeles@icr.ac.uk.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MGenetic Predictors of Prostate Cancer SurvivalR01CA244948 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI ROBERT J. KLEIN · 2021 to 2026
$4.1MInfluence of intra-individual variability in serial screening samples on clinical decision-making for risk stratification and biopsy by a single PSA and additional markersU01CA266535 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI JAMES A EASTHAM · 2022 to 2026
$2.0MNCI NIH HHS P30 CA008748NCI NIH HHS R01 CA244948NCI NIH HHS U01 CA266535
Abstract
BACKGROUND AND
objectiveBRCA1 and BRCA2 pathogenic germline variants (PGVs) are associated with higher risk of prostate cancer (PC). The IMPACT study evaluated the utility of targeted prostate-specific antigen (PSA) screening in BRCA1/BRCA2 PGV carriers. Here we report outcomes after five rounds of PSA screening in IMPACT.
methodsBetween 2005 and 2015, 3063 participants aged 40-69 yr (median 54 yr) were recruited from 65 centres in 20 countries in two cohorts: (1) BRCA1/BRCA2 PGV carriers (915 BRCA1, 901 BRCA2); and (2) age-matched noncarriers for a familial PGV (727 BRCA1 and 520 BRCA2 noncarriers). Annual PSA screening was performed, with PSA >3.0 ng/ml used as the indication for prostate biopsy. Our aim was to identify differences by PGV status in (1) the incidence of PC and of clinically significant PC (csPC; grade group ≥2) and (2) tumour stage and characteristics after five screening rounds. KEY FINDINGS AND LIMITATIONS: There was no statistically significant difference in PC incidence between BRCA1/BRCA2 PGV carriers and noncarriers. csPC incidence was significantly higher for BRCA2 PGV carriers than for noncarriers (3.1% vs 1.3%; p = 0.04). Among men with PC, the proportion of tumours with National Comprehensive Cancer Network intermediate unfavourable/high risk was higher in the BRCA1/BRCA2 PGV groups versus the corresponding group without PGVs (BRCA2: 65% vs 32%, p = 0.029; BRCA1: 56% vs 18%, p = 0.0017). There were no T4 or metastatic PC cases. Pathology after radical prostatectomy revealed tumour upgrading for 7/23 (26%) BRCA1 PGV carriers and 10/34 (26%) BRCA2 PGV carriers, with no tumour upgrading for men without PGVs. Study limitations include the biopsy compliance rate and changes in PC diagnostic pathways since 2005. CONCLUSIONS AND CLINICAL IMPLICATIONS: Annual PSA screening in BRCA2 PGV carriers confirmed a higher incidence of csPC and detection of clinically relevant tumours in comparison to noncarriers. For the first time, we confirm that PSA screening in BRCA1 PGV carriers results in early detection of NCCN IR-U/HR PC. Systematic PSA screening is recommended for BRCA2 PGV carriers and should be considered for BRCA1 PGV carriers.
Indexed as
BRCA1 ProteinBRCA2 ProteinEarly Detection of CancerGenes, BRCA1Genes, BRCA2Germ-Line MutationProstate-Specific AntigenProstatic NeoplasmsAdultAgedGenetic Predisposition to DiseaseHeterozygoteHumansIncidenceKallikreinsMaleBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanKallikreinsProstate-Specific AntigenBRCA1BRCA2Cancer screeningProstate cancerProstate-specific antigen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.